Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22
You may also be interested in...
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
FDA’s decision to approve the 150 mg strength of Boehringer Ingelheim GmbH’s antithrombotic Pradaxa (dabigatran), but not the 110 mg dose, reflects agency doubts about the ability of risk management tools to change prescriber behavior that is likely to result in inappropriate use of a less effective dose.